Evidence map›Paper›PMID 39397208›Full record

ArticleBreast cancer research and treatment2025

Trends in management and related outcomes for occult primary breast cancer.

M LaBella, R E Lile-King, C B Agala, P M Spanheimer, D W Ollila, K K Gallagher, J M Selfridge

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M LaBellaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
R E Lile-KingDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
C B AgalaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
P M SpanheimerDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
D W OllilaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
K K GallagherDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
J M SelfridgeDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA. Julia_Selfridge@med.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC Integrated Translational Oncology Program (UNC-iTOP)T32CA244125 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM, Jen Jen Yeh · 2019 to 2026
$3.9M
Cell cycle paths as a framework for understanding drug resistance in tumor cell subpopulationsR01CA280482 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeanette Gowen Cook, Michael James Emanuele · 2024 to 2026
$1.8M
Predicting Endocrine Therapy Response In Male Breast TumorsR37CA292075 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jose P. Leone, Philip M. Spanheimer · 2024 to 2026
$1.8M
Repurposing RET Inhibitors for Endocrine Resistant Breast CancerK08CA280388 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Philip M. Spanheimer · 2023 to 2026
$812k
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill P30CA016086national inst K08CA280388NCI NIH HHS K08 CA280388NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA280482NCI NIH HHS R37 CA292075NCI NIH HHS T32 CA244125
6 · The paper itself

Abstract

purposeOccult Primary Breast Cancer (OPBC) is a rare clinical condition in which breast cancer is located within the axillary lymph nodes, but no primary tumor is identified in the breast. We evaluated trends of neoadjuvant chemotherapy (NAC) use and subsequent axillary procedures in OPBC as well as outcomes for these patients.

methodsThe National Cancer Database was used to identify adult women with cT0N1-3M0 breast cancer between 2012 to 2021 that underwent axillary lymph node surgery. Kaplan-Meier curves were used to evaluate survival between groups.

results2759 patients met inclusion criteria. 86.2% underwent ALND alone in 2012, and this decreased to 65.6% in 2021. 4.7% underwent SLNB alone in 2012 and this increased to 16.2% in 2021 (p < 0.001). For patients who had undergone NAC, 46.4% of ALND patients had nodal pathologic complete response (nPCR), compared to 42.7% of SLNB + ALND and 66.4% of SLNB only patients. For patients with nPCR, there was no difference in overall survival (OS) between ALND, SLNB + ALND, and SLNB alone groups (p = 0.9912).

conclusionMost OPBC patients were treated with ALND, with a modest increase towards SLNB use during the study period. There was no difference in OS with respect to axillary surgical procedure in our population for those with nPCR after NAC. This suggests that for carefully selected OPBC patients with an excellent clinical response to NAC and negative SLNB, omission of ALND may be considered.

Indexed as

Breast NeoplasmsNeoplasms, Unknown PrimaryAdultAgedAxillaChemotherapy, AdjuvantDisease ManagementFemaleHumansKaplan-Meier EstimateLymphatic MetastasisLymph Node ExcisionLymph NodesMiddle AgedNeoadjuvant TherapyNeoplasm StagingAxillaBreast cancerOccult

Identifiers

PMID39397208
PMCPMC11875011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.